FIELD: biotechnology.
SUBSTANCE: invention relates to production of trispecific binding proteins binding the target HIV protein. Invention provides an agent for eliminating the HIV-1 reservoir by activating CD3 antibodies, co-activating the target T-cell protein antibodies, for example, to CD28 and subsequent destruction of activated cells of HIV-1 reservoir by means of antibodies to HIV/to CD28 by involvement of activated CD8 T-cells, which provides a potential strategy for attack on HIV-1 reservoir.
EFFECT: invention can be used in medicine for prevention or treatment of HIV infection.
33 cl, 2 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| UNNATURAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF APPLICATION | 2015 |
|
RU2687150C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
